-
-
-
[1] 王冠军,李薇,崔久嵬,等.血清游离轻链检测分析[M].4版.长春:吉林大学出版社,2010:195-202.
[2] [KG*1]KATZMANN J A,CLARK R J,ABRAHAM R S,et al.Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains[J].Clin Chem,2002,48: 1437-1444.
[3] [KG*1]BRADWELL A R,MEAD G P.Biology of immunoglobulin light chains[M]//BRADWELL A R,MEAD G P,CARR-SMITH H D.Serum Free Light Chain Analysis.4th ed.Birmingham: The Binding Site Ltd,2006: 13-33,81-90.
[4] [KG*1]DISPENZIERI A,KYLE R,MERLINI G,et al.International myeloma working group.International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders[J].Leukemia,2009,23:215-224.
[5] [KG*1]SNOZEK C L,KATZMANN J A,KYLE R A,et al.Prognostic value of the serum-free light chain ratio in patients with newly diagnosed myeloma and proposed incorporation into the International Staging System[J].Leukemia,2008,22: 1933-1937.
[6] [KG*1]KYRTSONIS M C,VASSILAKOPOULOS T P,KAFASI N,et al.Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma[J].Br J Haematol,2007,137:240-243.
[7] [KG*1]VAN RHEE F,BOLEJACK V,HOLLMIG K,et al.High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis[J].Blood,2007,110: 827-832.
[8] [KG*1]GREIPP P R,SAN MIGUEL J,DURIE B G,et al.International staging system for multiple myeloma[J].J Clin Oncol,2005,23: 3412-3420.
[9] [KG*1]DURIE B G,HAROUSSEAU J L,MIGUEL J S,et al.International uniform response criteria for multiple myeloma[J].Leukemia,2006,20: 1467-1473.
[10] AVET-LOISEAU H,FACON T,GROSBOIS B,et al.Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed,but correlate with natural history,immunological features,and clinical presentation[J].Blood,2002,99: 2185-2191.
[11] FONSECA R,HARRINGTON D,OKEN M,et al.Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) Study[J].Cancer Res,2002,62: 715-720.
[12] CHANG H,TRIEU Y,QI X,et al.Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains[J].Leuk Res,2011,35: 95-98.
[13] FONSECA R,BLOOD E,RUE M,et al.Clinical and biologic implications of recurrent genomic aberrations in myeloma[J].Blood,2003,101:4569-4575.
[14] HU Y, CHEN L, SUN C Y, et al. Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients[J]. Chinese Med J, 2011,124:2981-2985.
[15] JIANG A,REECE D,CHANG H.Genomic stratification of multiple myeloma treated with novel agents[J].Leuk Lymphoma,2012,53:202-207.
[16] FONSECA R,BARLOGIE B,BATAILLE R,et al.Genetics and cytogenetics of multiple myeloma: A workshop report[J].Cancer Res,2004,64: 1546-1558.
[17] 蒋元强,陈丽娟,朱雨,等.多重荧光原位杂交技术检测多发性骨髓瘤复杂核型异常[J].中华医学遗传学杂志,2010,27(4): 441-444.
[18] ROSS F,AVET-LOISEAU H,AMEYE G,et al.Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders[J].Haematologica,2012,Feb 27.[Epub ahead of print].
[19] JOURDAN M,FERLIN M,LEGOUFFE E,et al.The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells[J].Br J Haematol,1998,100: 637-646.
[20] AHMANN G J,JALAL S M,JUNEAU A L,et al.A novel three-color,clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies[J].Cancer Genet Cytogenet,1998,101: 7-11.
[21] MULLIGAN M,SMITH S,TALMI D.Whole body radiography for bone survey screening of cancer and myeloma patients[J].Cancer Invest,2008,26: 916-922.
[22] MULLIGAN M E.Skeletal abnormalities in multiple myeloma[J].Radiology,2005: 234; 213-214.
[23] GHANEM N,LOHRMANN C,ENGELHARDT M.Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey[J].Eur Radiol,2006,16:1005-1014.
[24] FECHTNER K,HILLENGASS J,DELORME S,et al.Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems[J].Radiology,2010,257: 195-204.
[25] HILLNER B E,SIEGEL B A,SHIELDS A F,et al.Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry[J].J Nucl Med,2008,49: 1928-1935.
[26] ALEXANDRAKIS M G,PASSAM F H,MALLIARAKI N,et al.Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone [CM(22*2]metabolism and other clinical parameters in untreated multiple myeloma patients[J].Clin Chim Acta,2002,325: 51-57.
[27] PACE L,CATALANO L,PINTO A,et al.Different patterns of technetium-99m sestamibi uptake in multiple myeloma[J].Eur J Nucl Med,1998,25:714-720.
[28] ZAMAGNI E,NANNI C,PATRIARCA F,et al.A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography,magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma[J].Haematologica,2007,92: 50-55.
-
计量
- 文章访问数: 172
- PDF下载数: 208
- 施引文献: 0
下载: